HK1220469A1 - 的人抗體 - Google Patents

的人抗體

Info

Publication number
HK1220469A1
HK1220469A1 HK16108451.7A HK16108451A HK1220469A1 HK 1220469 A1 HK1220469 A1 HK 1220469A1 HK 16108451 A HK16108451 A HK 16108451A HK 1220469 A1 HK1220469 A1 HK 1220469A1
Authority
HK
Hong Kong
Prior art keywords
grem
grem1
human antibodies
antibodies
human
Prior art date
Application number
HK16108451.7A
Other languages
English (en)
Inventor
Aris Economides
Vincent J Idone
Lori C Morton
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1220469A1 publication Critical patent/HK1220469A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16108451.7A 2013-03-14 2016-07-18 的人抗體 HK1220469A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782874P 2013-03-14 2013-03-14
US201361883218P 2013-09-27 2013-09-27
PCT/US2014/021471 WO2014159010A1 (en) 2013-03-14 2014-03-07 Human antibodies to grem 1

Publications (1)

Publication Number Publication Date
HK1220469A1 true HK1220469A1 (zh) 2017-05-05

Family

ID=50390267

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108451.7A HK1220469A1 (zh) 2013-03-14 2016-07-18 的人抗體

Country Status (18)

Country Link
US (3) US10377817B2 (zh)
EP (1) EP2970448B1 (zh)
JP (2) JP6581075B2 (zh)
KR (1) KR20150129718A (zh)
CN (1) CN105189548A (zh)
AU (1) AU2014241442B2 (zh)
BR (1) BR112015021979A2 (zh)
CA (1) CA2904644C (zh)
CL (1) CL2015002603A1 (zh)
EA (1) EA201591762A1 (zh)
ES (1) ES2898620T3 (zh)
HK (1) HK1220469A1 (zh)
IL (1) IL240769A0 (zh)
MX (1) MX369574B (zh)
PH (1) PH12015501865A1 (zh)
SG (2) SG11201506459PA (zh)
WO (1) WO2014159010A1 (zh)
ZA (1) ZA201506113B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9631011B2 (en) * 2012-03-15 2017-04-25 Snu R&Db Foundation Gremlin-1 antibody
CN105189548A (zh) 2013-03-14 2015-12-23 瑞泽恩制药公司 Grem1的人抗体
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
CN106399316B (zh) * 2016-08-26 2019-03-01 西安交通大学第一附属医院 用于识别Gremlin-1的核酸适配子及其应用
EP3504238A1 (en) * 2016-08-29 2019-07-03 Regeneron Pharmaceuticals, Inc. Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
US11702481B2 (en) * 2016-12-16 2023-07-18 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CA3055305A1 (en) 2017-03-22 2018-09-27 Bluefin Biomedicine, Inc. Anti-tmeff1 antibodies and antibody drug conjugates
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
CA3102743A1 (en) * 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
CA3162181A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
EP4232475A1 (en) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
EP4277927A1 (en) * 2021-01-18 2023-11-22 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2023203177A1 (en) * 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
WO1998033918A1 (en) 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405192B2 (en) 2001-10-31 2008-07-29 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
EP1777519A1 (en) 2001-10-31 2007-04-25 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP1855722A2 (en) 2005-02-24 2007-11-21 Novo Nordisk Health Care AG Compounds for stabilizing factor vii polypeptide formulations
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
DK2041177T3 (da) 2006-06-02 2012-02-27 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
PL2644594T3 (pl) 2007-09-28 2018-01-31 Pfizer Ukierunkowanie na komórki nowotworowe za pomocą nanocząstek
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
US9631011B2 (en) 2012-03-15 2017-04-25 Snu R&Db Foundation Gremlin-1 antibody
CN105189548A (zh) 2013-03-14 2015-12-23 瑞泽恩制药公司 Grem1的人抗体

Also Published As

Publication number Publication date
CA2904644A1 (en) 2014-10-02
IL240769A0 (en) 2015-10-29
ES2898620T3 (es) 2022-03-08
SG11201506459PA (en) 2015-09-29
MX369574B (es) 2019-11-13
AU2014241442A1 (en) 2015-10-15
EA201591762A1 (ru) 2015-12-30
MX2015011616A (es) 2015-12-17
BR112015021979A2 (pt) 2017-08-29
CN105189548A (zh) 2015-12-23
JP2019151654A (ja) 2019-09-12
AU2014241442B2 (en) 2018-11-15
US20200157194A1 (en) 2020-05-21
ZA201506113B (en) 2016-07-27
JP2016519650A (ja) 2016-07-07
CA2904644C (en) 2022-09-20
JP6581075B2 (ja) 2019-09-25
CL2015002603A1 (es) 2016-03-04
EP2970448B1 (en) 2021-11-03
SG10201707518YA (en) 2017-10-30
US20160024195A1 (en) 2016-01-28
EP2970448A1 (en) 2016-01-20
US11634480B2 (en) 2023-04-25
US20230192831A1 (en) 2023-06-22
US10377817B2 (en) 2019-08-13
WO2014159010A1 (en) 2014-10-02
PH12015501865A1 (en) 2015-12-07
KR20150129718A (ko) 2015-11-20

Similar Documents

Publication Publication Date Title
HK1220469A1 (zh) 的人抗體
HK1220468A1 (zh) 的人抗體
IL262804A (en) Antibodies to human pac1
HK1219961A1 (zh) 人抗α型干擾素抗體
HK1219962A1 (zh) 人抗白細胞介素- 抗體
HK1205147A1 (zh) 截短的人乳頭瘤病毒 蛋白
GB201322250D0 (en) Human targets l
EP2955226A4 (en) ANTIBODIES AGAINST HUMAN NRG1 PROTEIN
GB201310748D0 (en) Student's clinic
GB201311519D0 (en) Concept 39
GB201311503D0 (en) Concept 38
GB201311551D0 (en) Concept 66
GB201311545D0 (en) Concept 69
GB201311469D0 (en) Concept 12 12
GB201311483D0 (en) Concept 48
GB201311486D0 (en) Concept 50
GB201311488D0 (en) Concept 51
GB201311489D0 (en) Concept 52
GB201311490D0 (en) Concept 53
GB201311491D0 (en) Concept 54
GB201311499D0 (en) Concept 7
GB201311501D0 (en) Concept 37
GB201311542D0 (en) Concept 70
GB201311540D0 (en) Concept 72
GB201311522D0 (en) Concept 40